Related Experiment Video

Updated: Jan 19, 2026

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

10.3K

Rho GDP dissociation inhibitors as potential targets for anticancer treatment

Baolin Zhang1

  • 1Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, 29 Lincoln Dr., Bldg. 29A, Rm. 2B-24, Bethesda, MD 20892, USA. Baolin.Zhang@FDA.HHS.GOV <Baolin.Zhang@FDA.HHS.GOV>

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|June 30, 2006
PubMed

Insights

Rho GDP dissociation inhibitors (RhoGDIs) regulate Rho GTPases, impacting cell growth and cancer. Aberrant RhoGDI expression in tumors suggests a role in cancer progression and potential therapeutic targeting.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Rho GDP dissociation inhibitors (RhoGDIs) are key regulators of Rho GTPases, crucial for cell growth and malignant transformation.
  • While known to inhibit Rho activity, RhoGDIs can also positively regulate Rho GTPases by directing them to membranes or preventing caspase degradation.

Purpose of the Study:

  • To review the dual regulatory roles of RhoGDIs in Rho GTPase signaling.
  • To highlight the involvement of RhoGDIs in tumorigenicity and cancer progression.
  • To explore the potential of targeting RhoGDIs for novel anticancer therapies.

Main Methods:

  • Literature review of studies on RhoGDI function and expression.
  • Analysis of RhoGDI roles in normal cellular processes and cancer.
  • Examination of evidence linking RhoGDI dysregulation to tumor development.

Main Results:

  • RhoGDIs exhibit context-dependent dual roles, acting as both inhibitors and positive regulators of Rho GTPases.
  • Aberrant RhoGDI expression is observed in human tumors, correlating with cancer progression.
  • RhoGDIs influence cancer cell behavior through modulation of Rho GTPase activity and localization.

Conclusions:

  • RhoGDIs play a complex role in regulating Rho GTPase signaling, with significant implications for cancer.
  • Dysregulation of RhoGDI function contributes to tumorigenesis and cancer progression.
  • Targeting RhoGDIs presents a promising avenue for developing new anticancer treatments.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.4K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.8K

Related Concept Videos

G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.6K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.9K